Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2014 Dec;23(134):405-7.
doi: 10.1183/09059180.00009614.

Asthma: still a promising future?

Pascal Chanez  1 , Marc Humbert  2
Affiliations
Editorial

Asthma: still a promising future?

Pascal Chanez et al. Eur Respir Rev. 2014 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Disclosures can be found alongside the online version of this article at err.ersjournals.com

References

    1. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012; 18: 716–725. - PubMed
    1. Bourdin A, Molinari N, Vachier I, et al. . Prognostic value of cluster analysis of severe asthma phenotypes. J Allergy Clin Immunol 2014 [In press DOI: 10.1016/j.jaci.2014.04.038]. - PubMed
    1. Chung KF, Wenzel SE, Brozek JL, et al. . International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343–373. - PubMed
    1. Humbert M, Beasley R, Ayres J, et al. . Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60: 309–316. - PubMed
    1. Deschildre A, Marguet C, Salleron J, et al. . Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. Eur Respir J 2013; 42: 1224–1233. - PubMed

Publication types